drugset

drugset / Trial / NCT00036192

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

NCT00036192 ↗

Phase 2 Completed 200 enrolled Astellas Pharma Inc Astellas Pharma US, Inc. · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to assess the safety and efficacy of FK614 in type 2 diabetic subjects receiving sulfonylurea (SU) monotherapy.

Timeline

Start: 2002-02
Primary completion: —
Completion: 2006-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FK614	Unknown	—	—

Indications